title: In vitro and in vivo evaluation of thermosensitive chitosan hydrogel for sustained release of insulin.
abstract: Injectable In situ gel-forming chitosan/β-glycerol phosphate (CS/β-Gp) solution can be introduced into the body in a minimally invasive manner prior to solidifying within the target tissue. This hydrogel is a good candidate for achieving a prolonged drug delivery system for insulin considering its high molecular weight. In addition to the physicochemical characterization of this hydrogel, in vitro and in vivo applications were studied as a sustained insulin delivery system. In the in vitro release studies, 19-63% of total insulin was released from the CS/β-Gp hydrogel within 150 h at different β-Gp and insulin concentrations. The best formulation was selected for in vivo experimentation to control the plasma glucose of diabetic mice models. The hypoglycemic effect of this formulation following subcutaneous injection in diabetic mice lasted 5 d, significantly longer than that of free insulin solution which lasted several hours.
authors.affiliation: a Biomedical Engineering Group, Department of Chemical Engineering .
authors.forename: Farzaneh
authors.initials: F
authors.lastname: Ghasemi Tahrir
authors.affiliation: a Biomedical Engineering Group, Department of Chemical Engineering .
authors.forename: Fariba
authors.initials: F
authors.lastname: Ganji
authors.affiliation: b Department of Physiology , Tarbiat Modares University , Tehran , Iran , and.
authors.forename: Ali Reza
authors.initials: AR
authors.lastname: Mani
authors.affiliation: c Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences , Mashhad , Iran.
authors.forename: Elham
authors.initials: E
authors.lastname: Khodaverdi
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods; D048271:Chitosan / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D016503:Drug Delivery Systems / Q000379:methods; D005994:Glycerophosphates / Q000737:chemistry; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D007328:Insulin / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D051379:Mice; D019999:Pharmaceutical Solutions / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D013696:Temperature
chemical_list: D003692:Delayed-Action Preparations; D005994:Glycerophosphates; D007004:Hypoglycemic Agents; D007328:Insulin; D019999:Pharmaceutical Solutions; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D048271:Chitosan; C031463:beta-glycerophosphoric acid
keywords: diabetic mice; in situ gel-forming; injectable; subcutaneous injection; β-glycerolphopshate